Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPO receptor agonist discontinuation in adults with persistent or chronic ITP
NL-OMON54835Phase 4Active, not recruiting
- Sponsor
- HagaZiekenhuis
- Start
- Jul 2017
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in immune thrombocytopenia (ITP), sponsored by HagaZiekenhuis. Primary endpoint: Treatment success after 1 year of TPO-RA therapy. Started Jul 2017; status: active, not recruiting.
02
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON54835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54835.